BIBW2992 (afatinib), a second generation, irreversible EGFR-TKI developed against HER2, HER4 and EGFR, including the T790 M mutation [5], has been approved by the FDA for the treatment of locally advanced and/or metastatic NSCLC. This evidence concerns the gene ERBB4 and non-small cell lung carcinoma.